PD-1 / NFAT Reporter - Jurkat Recombinant Cell Line

Request a free sample of our new LIVE-Step™ Cell Assay System with your purchase of this product, indicating your order confirmation number, or visit LIVE-Step™ Cell Assay System for a 50% discount on the purchase of any size LIVE-Step reagent.

Catalog #
60535
$11,375 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

PD-1/NFAT Reporter Jurkat Recombinant Cell Line is a Jurkat cell line that expresses human PD-1 (Programmed Cell Death 1, also known as PDCD1, SLEB2, CD279, GenBank Accession #NM_005018), and the firefly luciferase reporter under the control of NFAT response elements located upstream of the minimal TATA promoter. Stimulation of NFAT can therefore be monitored by measuring luciferase activity. 

PD-1 expression was verified by flow cytometry and this cell line was functionally validated with Anti-PD-1 and Anti-PD-L1 neutralizing antibodies in co-culture assays.

 

PD-1 Jurkat NFAT Cell Line BPS Bioscience

Figure 1: Illustration of the mechanism of action of PD-1/NFAT Reporter Jurkat Recombinant Cell Line in a co-culture assay.
The TCR (T cell receptor) activator present at the surface of PD-L1/TCR Activator CHO cells stimulate the TCRs in Jurkat T cells, whereas overexpression of PD-L1 on the CHO cell line engages Jurkat PD-1, blocking TCR activation signaling and preventing activation of NFAT. Addition of a neutralizing anti-PD-1 or anti-PD-L1 antibody to the co-culture releases the PD-L1/PD-1 complex and results in TCR activation and increased NFAT activity, which translates into increased luciferase reporter signal.

Interested in screening and profiling inhibitors, blocking antibodies, or activators of PD-1 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.

This product has been cited 37 times.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Programmed cell death 1, PDCD1, PD-1, PD1, SLEB2, CD279, HPD-L, PD1/NFAT, PD-1 NFAT, PD-1/NFAT
Product Info
Storage and Usage
Citations37
Host Cell Line
Jurkat (clone E6-1), human T lymphoblast, suspension
Species
Human
Supplied As
Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience, #79796)
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
Thaw Medium 2 BPS Bioscience #60184
Growth Medium 2A BPS Bioscience #60190


Materials Required for Cellular Assay

Name Ordering Information
PD-L1 / TCR Activator - CHO Recombinant Cell Line BPS Bioscience #60536
NFAT Luciferase Reporter Jurkat Cell Line BPS Bioscience #60621
Thaw Medium 3 BPS Bioscience #60186
Anti-PD-1 Neutralizing Antibody  BPS Bioscience #71120
Nivolumab (anti-PD-1) SelleckChem #A2002
Anti-PD-L1 Neutralizing Antibody BPS Bioscience #71213
ONE-Step™ Luciferase Assay System BPS Bioscience #60690 
96-well tissue culture-treated white clear-bottom assay plate  
Luminometer  
UniProt #
Q15116
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

PD-L1 and PD-L2 binding to PD-1, a receptor expressed on T-cells, negatively regulates immune responses. The PD-1 ligands PD-L1 and PD-L2 are found on the surface of most cancer cells, and their interaction with the receptor PD-1 inhibits T cell activity and allows cancer cells to escape immune surveillance. This pathway is also involved in regulating autoimmune responses. Therefore, these proteins (termed immune checkpoints) are promising therapeutic targets for many types of cancer as well as multiple sclerosis, arthritis, lupus, and type I diabetes. Checkpoint inhibitors have remarkable efficacy in a wide range of cancer types and have revolutionized cancer treatment.  The PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab and PD-L1 inhibitors atezolizumab, avelumab, and durvalumab are all FDA-approved drugs for immuno-therapy.